Get started
Moleculin Biotech, Inc.Moleculin Biotech, Inc.Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MBRX trade ideas

MBRX Annamycin Fast Track and Orphan Drug Designation from FDAMoleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which is at all time low now. 52 Week Range 1.64 - 8.78 My price target is $3.8
NASDAQ:MBRXLong
by TopgOptions
$MBRX Moleculin biotech $MBRX seems to have grit for sellThe Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data far above the expectations of analysts. Recently a reverse split of the stock has also been carried out that reduces the number of titles in circulation. In fact, today the Miracle Viewer indicator that analyzes the graph in search of interests in the market of large players shows an increase in LONG positions by the institutions so you could implement an upward price action. Analyzing the chart, the title seems to have some obstacles along the way but if the interests from the big will remain high will probably be surpassed with limited retracements, according to the signal of Marketmiracle the stock could go even further pushing at the price of 15,50 USD but I would not want in my graphical analysis to exceed the level I indicate as target as it is already a remarkable increment and during the path the title could lose strength. I will try to free cash and enter the stock also because at the moment the balance seems to be shifting a lot on pharmaceuticals and biotech companies so personally I think this is a good opportunity. ( see related other ideas on other biotech and pharma titles ) We will see in the next hours and days if the forecast of Marketmiracle will prove effective. This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:MBRXLong
by MarketMiracleAdvisor
2
100% Survival Achieved in Osteosarcoma Lung MetastasesMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals. Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 34 times the level of doxorubicin, which may account for the 100% survival rate attained in this most recent osteosarcoma lung metastases study. Moleculin recently announced that the FDA has allowed the Company's request for investigational new drug (IND) status in order to study Annamycin for the treatment of soft tissue sarcoma metastasized to the lungs. In addition, the FDA granted Orphan Drug Designation for Annamycin for the treatment of soft tissue sarcomas. "We expect that one, and potentially two, clinical trials in sarcoma lung metastases should be up and running this year." finance.yahoo.com
NASDAQ:MBRX
by AlenCiken
$MBRX (fm @Marcoux)Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
NASDAQ:MBRXLong
by BADQOMOCAWGOWLD
$MBRX Potential Break Above 200ma Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
NASDAQ:MBRXLong
by DEXWireNews
1
MBRX 30 Minutes Chart AnalysisSaturday July 25th, 2020 • • • Disclaimer• • • Please don't take this as a financial advice, remember I'm not a professional analytic, this whole idea is based on my knowledge, interpretation and opinion. This is only my Idea, don't buy or sell because of my idea. Do your own research in the company before deciding either buy or sell. Remember there is always a risk of losing money when you trade or invest in any stock, you must decide at your own risk. Indicators in the Chart • SMA 200 • SMA 60 • SMA 50 • Pivot Reversal Strategy • RSI • MACD • Bollinger Bands • EMA 15 • Fibonacci Retracement Chart patterns • The chart is doing the same pattern of the last run. After the pump did a drop and entered in a consolidation zone which looks like is getting to the end of the consolidation. Interpretation of the indicators • RSI got oversold and now looks like is leaving the consolidation area and preparing to start moving. • The MACD also show a consolidation but is getting closer to the 0.00 area and curling Down. • Bollinger Band are getting thinner and probably will break down. • Candles trading below the EMA 15, above the SMA 200, SMA 60 and SMA 50. • Fibonacci is showing a range of possible Price Targets. In the green area I think is a secure area to lock profits $1.28 to $1.38. If the trend continue it can reach from $1.38 to $1.74. Also, I think the Stock price can reach the $2.11 area if the pump is like the last one. All these price targets are from the Fibonacci Retracement. Fundamental information • www.finviz.com What is doing the company? • The company is working in a potential Covid-19 Treatment. • FDA is waiting positive results from an animal model to submit a request for investigational New Drug. Pipeline • www.moleculin.com Opinion The company looks healthy and they have a couple of clinical trials in development. One of them is the COVID-19 treatment which is the new gameplay for most traders on 2020. Their COVID-19 trials still in the beginning of the development and with some positive news it can go higher because of the hype of COVID stocks. I think the stock have the potential to reach $2 in a short term. Chart patterns looks favorable and news looks favorable for this stock. It has a good volume AVG in the 90 days period (6.29M). Probably it can dip a little bit more before moving up. But I don’t think the stock will go lower than $1.00. Remember do your own research on the company and don’t buy or sell because of my opinion. This is not a financial advice or recommendation; this is my idea and interpretation. References www.finviz.com finance.yahoo.com www.marketwatch.com www.moleculin.com ir.moleculin.com
NASDAQ:MBRXLong
by Making_Profit
Is $MBRX- The Best Biotech with the most upside Potential Is $MBRX- The Best Biotech with the most upside Potential Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and $MBRX break through with STAT3 inhibitors is a game-changer for treating cancer patients. As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term.. One you might want to research and stick away in your IRA .. As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
NASDAQ:MBRXLong
by InvisbleHand
1
Moleculin Biotech, Inc COVID-19 potentialNano cap Moleculin Biotech (MBRX +47.5%) rallies on a healthy 15x surge in volume in reaction to its agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on the company's line-up of molecular inhibitors, including lead candidate WP1122, to assess their antiviral properties against a range of viruses, including coronavirus. WP1122 is a prodrug of 2-DG (2-deoxy-D-glucose), a dual decoy of simple sugar glucose and mannose (a kind of sugar related to glucose) that may be effective in treating viral infection. Emerging research on the role of glucose and mannose metabolism in viral activity has apparently been encouraging. Under the terms of the collaboration, Moleculin will supply WP1122, related inhibitors and technical support while UTMB will conduct testing in a range of viral disease models, including COVID-19. Source seekingalpha Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
NASDAQ:MBRX
by DEXWireNews
2
$MBRX KEEP ON WATCHLIST, VOLUME & PRICE SPIKE PREMARKETSet your alerts for this stock has a history of 100% spikes, price up premarket on no news? Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors.
NASDAQ:MBRXLong
by DEXWireNews